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Valspodar, a P-glycoprotein modulator, affects pharmacokinetics of doxorubicin when administered in combination, resulting in
doxorubicin dose reduction. In animal models, valspodar has minimal interaction with pegylated liposomal doxorubicin (PEG-LD). To
determine any pharmacokinetic interaction in humans, we designed a study to determine maximum tolerated dose, dose-limiting
toxicity (DLT), and pharmacokinetics of total doxorubicin, in PEG-LD and valspodar combination therapy in patients with advanced
malignancies. Patients received PEG-LD 20–25mgm
 2 intravenously over 1h for cycle one. In subsequent 2-week cycles, valspodar
was administered as 72h continuous intravenous infusion with PEG-LD beginning at 8mgm
 2 and escalated in an accelerated
titration design to 25mgm
 2. Pharmacokinetic data were collected with and without valspodar. A total of 14 patients completed at
least two cycles of therapy. No DLTs were observed in six patients treated at the highest level of PEG-LD 25mgm
 2. The most
common toxicities were fatigue, nausea, vomiting, mucositis, palmar plantar erythrodysesthesia, diarrhoea, and ataxia. Partial
responses were observed in patients with breast and ovarian carcinoma. The mean (range) total doxorubicin clearance decreased
from 27 (10–73) mlh
 1m
 2 in cycle 1 to 18 (3–37) mlh
 1m
 2 with the addition of valspodar in cycle 2 (P¼0.009). Treatment
with PEG-LD 25mgm
 2 in combination with valspodar results in a moderate prolongation of total doxorubicin clearance and half-life
but did not increase the toxicity of this agent.
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Resistance to chemotherapeutic agents is an obstacle to the
successful treatment of malignancies. Resistance has been
attributed, in part, to the expression of the MDR1 gene and its
protein product, P-glycoprotein (Gottesman et al, 2002). P-glyco-
protein, a member of the ATP-binding cassette superfamily of
transmembrane transporters, prevents the intracellular accumula-
tion of many natural product-derived cytotoxic agents (Gottesman
et al, 2002). As a result, targeted inhibition of P-glycoprotein by
agents administered in combination with chemotherapeutic agents
has been attempted (Ford et al, 1996; Sikic, 1999; Leonard et al,
2003). One such agent, valspodar (PSC 833), a cyclosporine D
analogue, reverses P-glycoprotein-mediated resistance in vitro at
concentrations of 1000ngml
 1 (Twentyman and Bleehen, 1991). In
phase 1 studies, combinations of valspodar with single agent
etoposide, doxorubicin, paclitaxel, or vinblastine are feasible with
toxicities consisting of reversible cerebellar ataxia, myelosuppres-
sion, and hyperbilirubinemia (Boote et al, 1996; Giaccone et al,
1997; Fracasso et al, 2000; Bates et al, 2001, 2004; Chico et al, 2001;
Minami et al, 2001). Responses and disease stabilisation have been
noted in patients with carcinomas of the ovary, lung, and kidney
(Fracasso et al, 2000; Bates et al, 2001; Chico et al, 2001).
Valspodar has been shown to decrease the clearance of
etoposide, doxorubicin, paclitaxel, and vinblastine, and these
interactions have necessitated dose reductions of the anticancer
agents when given as single agents in combination with valspodar
(Boote et al, 1996; Giaccone et al, 1997; Fracasso et al, 2000; Bates
et al, 2001, 2004; Chico et al, 2001; Minami et al, 2001). Liposomal
encapsulated anticancer agents may be better suited to combina-
tion therapy with valspodar therapy, as one such agent, liposomal
doxorubicin, appears to have minimal pharmacokinetic interac-
tions with valspodar in mice, in comparison to free doxorubicin
(Krishna and Mayer, 1997; Krishna et al, 2000). Additional in vivo
studies have demonstrated that the elimination of liposomal
doxorubicin from the plasma via renal and hepatic mechanisms is
minimally affected by valspodar (Krishna et al, 1999). These
animal studies would suggest that the FDA-approved anticancer
agent, pegylated liposomal doxorubicin (PEG-LD) (Doxil
s) may
be administered at full dose in combination with valspodar to
patients with malignancies, thus allowing for equivalent anticancer
drug exposure with the added benefit of P-glycoprotein inhibition
and no additional toxicity.
Given the activity of PEG-LD in various malignancies, including
Kaposi’s sarcoma and breast and ovarian carcinoma (Northfelt
et al, 1998; Gordon et al, 2000; Campos et al, 2001; Sparano and
Winer, 2001), and its minimal interactions with valspodar in
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sanimal studies (Krishna and Mayer, 1997; Krishna et al, 1999,
2000), we proposed a phase I study with this combination. This
study was designed to determine the maximum tolerated dose
(MTD) and dose-limiting toxicity (DLT) using a one-patient-
per-cohort accelerated titration design as proposed by Simon
et al (1997). In addition, this study evaluated the toxicities
of the combination of PEG-LD and valspodar and investigated
the effects of valspodar on the pharmacokinetics of doxorubicin.
Treatment responses were observed, but were not a primary end
point.
PATIENTS AND METHODS
Patient eligibility
This study was initially written and approved for treatment of
patients with AIDS-related Kaposi’s sarcoma. However, given the
decline in Kaposi’s sarcoma with the use of highly active
antiretroviral therapy (HAART) therapy and the known activity
of PEG-LD in breast and ovarian malignancies, this protocol was
amended to include patients with a histologically documented
resistant or recurrent malignancies. A life expectancy 44 months,
age X18 years, and laboratory parameters (haemoglobin
X8gdl
 1, absolute neutrophil count X1000cellsml
 1, platelet
count X75000 cellsml
 1, creatinine p2.0mgdl
 1, SGOT p2 
the institutional upper limit of normal (ULN), and bilirubin
o1.5  the institutional ULN) were required. Prior cytotoxic or
radiation therapy had to be completed 4 weeks prior to enrollment.
Prior chemotherapy with PEG-LD and doxorubicin was permitted.
Patients with congestive heart failure or neuropathy (motor or
sensory), or with a history of prior PEG-LD or cyclosporine A
hypersensitivity were excluded. Any patient receiving medications
that are metabolised by the cytochrome P450 system including
calcium channel blockers, imidazole antifungal agents, anti-
convulsants, or macrolide antibiotics had to discontinue these
medications 48h prior to valspodar therapy, during valspodar
administration and up to 48h after the last dose of valspodar in a
cycle. The Cancer Therapy Evaluation Program (T97-0073),
Division of Cancer Treatment and Diagnosis, National Cancer
Institute (NCI) and the Washington University Human Studies
Committee approved this protocol. All patients provided their
signed informed consent prior to study entry.
Treatment plan
This study used a treatment cycle of 14 days, similar to the
treatment schedule of PEG-LD used by Northfelt et al, (1998) for
AIDS-related Kaposi’s sarcoma. In cycle 1, patients in dose levels 1
through 7 received PEG-LD (Doxil
s, Ortho Biotech Products, L.P.,
Raritan, NJ, USA) alone at 20mgm
 2 intravenously over 1h.
Patients in dose levels 8 and 9 received PEG-LD at 22 and
25mgm
 2 during cycle 1, respectively. Beginning with cycle 2,
PEG-LD was administered at a starting dose of 8mgm
 2 in
combination with a fixed dose of valspodar and dose escalated in
2mgm
 2 increments (dose levels 2–8) to a final dose escalation to
24mgm
 2 (dose level 9). However, the protocol was amended after
the treatment of patient #8 to change the final dose level to PEG-
LD 25mgm
 2 (administered every 2 weeks). Valspodar (PSC 833,
Amdray
s, Novartis Pharmaceuticals Corporation, East Hanover,
NJ, USA) is typically administered prior to the antineoplastic
agent. However, given the long half-life of PEG-LD, valspodar
was administered immediately after the PEG-LD infusion as a
1.42mgkg
 1h
 1 infusion over 2h and then reduced to
0.42mgkgh
 1 (10mgkgd
 1) for an additional 70h. Administered
in this way, valspodar maintains levels above 1000ngml
 1, the
concentration necessary to reverse P-glycoprotein-mediated re-
sistance in vitro, for 72h.
Patients were not treated at all dose levels because we utilised
the one-patient-per-cohort accelerated titration design (#4) as
proposed by Simon et al, 1997) described below. Briefly, this
design began with the treatment of one patient at the lowest dose
level (PEG-LD 8mgm
 2). Intrapatient double dose escalation (i.e.
4mgm
 2 vs usual single dose increments of 2mgm
 2) occurred at
the completion of each cycle unless the patient experienced a DLT
or two instances of grade X2 nonhaematologic toxicity during any
cycle. Provided the patient(s) on the previous dose level had no
DLT and less than two instances of grade 2 nonhaematologic
toxicity during any cycle, the next patient enrolled began therapy
at the new escalated dose level. Intrapatient and interpatient dose
escalation in the absence of the toxicity as defined above was
permitted, such that dose escalation could occur simultaneously
for two (or more) patients at different dose levels. Once a DLT or
two instances of grade X2 nonhaematologic toxicity occurred, the
accelerated escalation phase was stopped, and the design reverted
to a modified Fibonacci scheme with three patients enrolled at this
dose level. If zero of three patients experienced DLT, dose
escalation resumed in single dose increments (2mgm
 2). If one
of three experienced DLT, three more patients were enrolled at the
same dose level. If two of three patients experienced a DLT, the
previous dose level was expanded to six patients. The MTD was
that dose in which no greater than one of six patients experienced
a DLT.
Dose-limiting toxicity was defined during the second cycle only
as grade 4 neutropenia or thrombocytopenia of 47 days duration
or a failure to recover the absolute neutrophil count (ANC) to
X1000 cellsml
 1 or the platelet count to X75000 cellsml
 1 by day
21. Any grade 3 or 4 nonhaematologic toxicity excluding alopecia,
nausea, vomiting, fever, anorexia, or mucositis were also
considered dose-limiting. For valspodar, grade 3 or 4 cerebellar
dysfunction, despite a prior 25% dose reduction in valspodar, was
also considered a DLT.
Dose modifications and delays were permitted as follows: an
ANC o1000 cellsml
 1 or a platelet count o75000 cellsml
 1 by day
1 of the subsequent cycle necessitated a 1 week treatment delay.
PEG-LD doses were decreased by one dose level if the ANC was
o500 cellsml
 1 for 47 days (grade 4 neutropenia), if the patient
experienced febrile neutropenia, or if the ANC failed to recover
to X1000 cellsml
 1 by the next cycle. In the event of grade 3
skin toxicity, palmar-plantar erythrodysesthesia (PPE), or
mucositis, a 25% dose reduction occurred in the PEG-LD and
treatment was delayed until the toxicity resolved to a grade 1. In
the case of grade 3 cerebellar dysfunction, valspodar was reduced
by 25%.
Antitumour response was evaluated after the second cycle of
therapy (i.e. 4 weeks) and subsequently, after every four cycles (i.e.
every 8 weeks). Responses were defined according to the RECIST
criteria (Therasse et al, 2000) except for the patient with Kaposi’s
sarcoma, whose response was defined according to the criteria
used by the World Health Association (WHO Handbook, 1979).
Pharmacokinetic monitoring
During the first (PEG-LD alone) and the second (PEG-LD and
valspodar) cycles, patients had blood samples obtained at sites
contralateral to the infusion site and collected in heparinised tubes
before PEG-LD infusion, and 1, 2, 6, 8, 24, 48, and 72h after the
start of the PEG-LD infusion. Plasma samples were stored at
 701C until analyses.
Plasma (0.5ml) with internal standard (daunorubicin 1000ng)
was combined with 3% (vv
 1) triton X-100 (50ml), vortexed for
10s to disrupt the liposome, and vortex mixed with 65% (wv
 1)5 -
sulphosalicylic acid (50ml) for 10s to extract doxorubicin (Chin
et al, 2001). The reagent mixture (610ml) was then centrifuged at
14000r.p.m. for 10min at room temperature. The extracted
supernatant was removed and reconstituted in 75mlo f3M sodium
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sacetate and a final volume of 50ml was injected onto a column
using a fluorescence detection method. Briefly, a HPLC pump LC-
10AD and controller SCL-10A (Shimadzu Scientific instruments,
Columbia, MD, USA) were used to deliver a mobile phase of 50mM
potassium dihydrogen phosphate, pH 3.0: acetonitrile (75:25,
vv
 1) with 10mgml
 1 desipramine isocratically at a flow rate of
1.0mlmin
 1 to precolumn premier C18 (120A) and a Shimadzu
chromegabond
s TC 18 column (4.6 100mm, 5mm) (Shimadzu
Scientific Instruments, Columbia, MD, USA). Desipramine was
used to reduce doxorubicin adsorption to the HPLC system
(Gabizon et al, 1993). Samples were injected with a Shimadzu
SIL-10AD autosampler. Fluorescence detector RF 10AXL
(Shimadzu Scientific Instruments, Columbia, MD, USA) was used
to quantitate total doxorubicin concentrations in the presence of
the internal standard daunorubicin, using excitation and emission
wavelengths of 470 and 590nm, respectively. Total doxorubicin
concentrations were linear within the concentration range of 25–
1000ngml
 1. The lower limit of quantitation for this assay was
25ngml
 1. Samples containing concentrations above the highest
calibration standard were reanalysed after dilution with blank
plasma up to a 1:40 dilution. In all, 20 replicates of a low
(35ngml
 1), intermediate (150ngml
 1), and high (600ngml
 1)
concentration were repeated on three consecutive days to
determine the accuracy and precision of the assay. Intra-assay
variability was 1.9, 3.3, and 3.8% at 35, 150, and 600ngml
 1,
respectively. Interassay variability was within 5% across the linear
range of the calibration curve. All validation samples were within
10% of the corresponding spiked concentrations.
The disposition of total doxorubicin was fit with both one-and
two-compartment model with linear distribution and elimination.
The parameters estimated in the linear model included apparent
volume of the central compartment (V) and the intercompart-
mental first-order rate constants K12, K21, and K10. Pharmacoki-
netic parameters for each set of patient data were fit using an
iterative two-stage analysis with maximum-likelihood (ML)
estimation, as implemented in ADAPT II software (D’Argenio
and Schumitzky, 1979), and the median for each parameter was
then used as the revised initial estimates for the next ML iteration.
The median for each parameter was updated until the parameter
estimates for all parameters were stable (defined as no net change
to the second significant digit). Total doxorubicin concentration–
time data from each patient was fit individually for each cycle. All
modelling of cycle 2 data included any residual total doxorubicin
concentrations detectable in the pretreatment sample (time¼0).
Each data set was assessed for the goodness of model-curve fit by
an estimate of the variance for the predicted values, correlation
coefficients, and the Akaike information criterion (AIC) between
different models.
Area under the concentration vs time curves (AUC0-N) was
calculated by integration of the simulated concentration–time data
from the model estimates. Systemic clearance was calculated as
V K10. The alpha and beta elimination half-lives were calculated
using equations generated by ADAPT II software. The differences
in total doxorubicin clearance, terminal half-life, or total
doxorubicin AUC between cycle 1 and 2 were assessed using
Wilcoxon matched pairs test. The correlation between PEG-LD
dose and AUC was assessed using the Spearman’s rank test. All
comparisons were considered significant at Po0.05.
RESULTS
Patients
The characteristics of the 14 patients enrolled from March 1998
until December 2001 are summarised in Table 1. Six patients had
received prior therapy with doxorubicin and one patient had
received prior therapy with PEG-LD. Pegylated liposomal doxo-
rubicin and valspodar was first-line therapy for the patients with
hepatoma and Kaposi’s sarcoma.
Treatment administered
All patients completed at least two cycles of therapy, with cycle 1
containing PEG-LD alone and cycle 2 containing both PEG-LD and
valspodar (Table 2). A total of 69 combined PEG-LD and valspodar
treatment cycles were administered, (range 1–13). As per study
design, intrapatient double dose escalation was terminated after
patient #2 experienced a DLT (grade 3 PPE) at PEG-LD 24mgm
 2.
This patient with hepatoma received a total of 14 cycles after a 25%
dose reduction at cycle 5 and again at cycle 10 (see Table 2). The
traditional single-step dose escalation with three patients per dose
level was then initiated with patient #3 receiving PEG-LD
20mgm
 2, the previous dose level for which patient #2 had no
significant toxicities. Since no DLTs were observed at PEG-LD 20
and 22mgm
 2, six patients received PEG-LD 25mgm
 2 in
combination with valspodar.
In all, 90% of the 69 cycles of combined PEG-LD and valspodar
were administered on schedule. Seven cycles administered to four
patients (#2, 6, 12, and 14) were delayed due to PPE. These four
patients also underwent dose reductions (as noted in Table 2)
following the dose delay. In these four patients, all dose delays and
reductions occurred after receiving at least three cycles of PEG-LD
(one cycle of PEG-LD alone and several cycles in combination with
valspodar) at a dose of 420mgm
 2.
Toxicity
Table 3 summarises the haematologic toxicities for all treatment
cycles. Only two grade 3 haematologic toxicities were noted.
Patient #12 experienced grade 3 neutropenia and PPE after four
cycles of treatment with PEG-LD 25mgm
 2, which led to a
Table 1 Patient characteristics
Characteristics
No. of
patients
14
Age
Mean 54
Range 34–80
Sex
Male:female 2:12
ECOG performance status
03
19
22
Diagnosis
Breast 4
Colorectal 3
Sarcoma (leiomyosarcoma, Kaposi’s
sarcoma)
2
Other (hepatoma, ovarian, head and neck,
primary peritoneal, renal cell carcinoma)
5
Prior therapy
Chemotherapy 12
Median # of regimens (range) 3 (0–7)
Prior doxorubicin 6
Mean dose (range) in mgm
 2 337 (100–555)
Prior PEG-LD 1
Dose (mgm
 2) 279
Radiation therapy 7
PEG-LD¼pegylated liposomal doxorubicin.
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ssubsequent dose delay and reduction, and patient #4 experienced
grade 3 anemia requiring a red blood cell transfusion after cycle 1.
In addition, patients #5, 6, 8, and 14 with grade 2 anemia received
red blood cell transfusions, and patients #4, 5, 13, and 14 received
erythropoietin.
Table 4 summarises the most common nonhaematologic
toxicities. Grade 3 and 4 events were uncommon and consisted
primarily of PPE. Patient #9 developed the only grade 4 toxicity,
PPE, after receiving four cycles of PEG-LD 25mgm
 2. Patients #2,
6, 12, and 14 experienced grade 3 PPE after they received more
Table 2 Summary of all patients and treatment administered
Cycle # and dose of PEG-LD (mgm
 2)
Patient # 1
a 2 3 4 56789 1 0 1 1 1 2 1 3 1 4
1 20 8 12 16 20
2 20 16 20 24 18 18 18 18 18 13.5 13.5 13.5 13.5 13.5
3 2 02 02 02 0
42 0 2 0
52 0 2 0
6 20 22 22 16.5 16.5 16.5 16.5 12.4 12.4 12.4 12.4 12.4
7 2 22 22 22 2
8 2 22 22 22 2
9 2 52 52 52 5
10 25 25
11 25 25
12 25 25 25 25 18.75 18.75 18.75 18.75 18.75 18.75 18.75 18.75
13 25 25
14 25 25 25 25 25 18.75 18.75 18.75 18.75 18.75 14.06 14.06 14.06 14.06
aAll patients received PEG-LD (pegylated liposomal doxorubicin) alone for the cycle 1 and PEG-LD in combination with valspodar for all other cycles.
Table 3 Hematologic toxicities
Patient # PEG-LD (mgm
 2)
No. of PEG-LD and
valspodar cycles
a
ANC nadir mean
(range) (cellsll
 1)
Platelet nadir mean
(range) (10
3ll
 1)
Haemoglobin mean
(range) (gdl
 1)
1–14 20–25 0 3.803 (1.994–7.571) 271 (161–424) 11.2 (6.7–13.8)
18 4
b 2.631 (1.613–3.602) 220 (195–229) 13.5 (12.8–14.1)
21 6 1 3
c 3.106 (2.109–5.083) 399 (295–529) 12.1 (10.8–12.8)
3–5 20 5 3.730 (2.275–6.255) 311 (66–501) 10.2 (8.3–12.5)
6–8 22 17
d 2.826 (1.386–5.039) 265 (113–464) 11.0 (8.6–13.8)
9–14 25 30
e 2.298 (0.936–7.056) 298 (137–477) 11.6 (8.7–14.0)
aTotal number of cycles does not include cycle 1 (PEG-LD alone).
bPatient #1 had dose escalations of 12, 16, and 20mgm
 2.
cPatient #2 received dose escalations of 20 and
24mgm
 2 before dose reductions of 18mgm
 2 for five cycles and 13.5mgm
 2 for five cycles.
dPatient #6 was dose reduced to 16.5mgm
 2 for four cycles and 12.4mgm
 2
for five cycles.
ePatient #12 was dose reduced to 18.75mgm
 2 for five cycles and 14.06mgm
 2 for four cycles. Patient #14 was dose reduced to 18.75mgm
 2 for eight cycles.
PEG-LD¼pegylated liposomal doxorubicin.
Table 4 Most common nonhaematologic toxicities
Cycle 1
a All other cycles
b
Grade Grade
Toxicity 0 1 2 3 4 0 1 2 3 4
Constitutional
Fatigue/malaise 10 2 1 1 — 13 1 — — —
Dermatology
P P E 1 4———— 9 — — 4 1
Gastrointestinal
Diarrhoea 10 2 2 — — 10 2 1 1 —
Nausea/vomiting 9 4 1 — — 4 6 3 1 —
Stomatitis/dysphagia 14 ———— 7 5 2 — —
Infection w/o neutropenia 1 0 121 — 1 2 1 1 ——
Other
PEG-LD infusion reaction 13 — — 1 — 14————
Valspodar-related events — ———— 5 8 — 1 —
aPEG-LD (pegylated liposomal doxorubicin) alone.
bPEG-LD given in combination with valspodar.
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sthan three cycles of therapy at PEG-LD at doses exceeding
20mgm
 2. Other grade 3 events included fatigue, infection
without neutropenia (cellulitis), diarrhoea, nausea/vomiting,
PEG-LD infusion reaction, and valspodar-related ataxia. The
PEG-LD reaction consisted of flushing, tightness, and abdominal
pain. This resolved after administration of dexamethasone and
diphenhydramine and did not occur with subsequent cycles after
premedication with these agents. During the valspodar infusion,
nine patients developed symptoms consisting of perioral numb-
ness and tingling, paresthesias, chest discomfort, dizziness, light-
headedness, or ataxia. These symptoms were mild (grade 1) and
resolved shortly after the completion of the infusion except in
patient #13 who developed grade 3 ataxia which resolved several
days later. This patient was never retreated with PEG-LD and
valspodar due to progressive disease.
Response
Two of the 14 patients achieved a partial response (PR). Patient #6
who had received seven prior chemotherapy regimens for
metastatic breast carcinoma achieved a PR lasting for 9 weeks.
Patient #12 with ovarian carcinoma who had previously received
PEG-LD achieved a partial response for 19 weeks. After 12 cycles of
therapy, this patient requested that she be removed from the study,
as the infusion pump required for administration of valspodar was
inconvenient for her lifestyle. A patient with Kaposi’s sarcoma had
a near PR (49% decrease in target skin lesions). This patient had
s.d. for 12 weeks and after five cycles of therapy, this patient
refused additional therapy. An additional four patients with breast
(two patients), hepatoma, primary peritoneal, and rectal carci-
noma had stable disease (range 4–22 weeks). Patient #2 with
hepatoma received 13 cycles of the combination therapy with a
best response of stable disease. This patient was removed from
study to undergo curative surgical resection, although, at the time
of resection, this was not possible.
Pharmacokinetics
All patients had total doxorubicin pharmacokinetics performed
either alone and in combination with valspodar. Initial evaluation
with a one-compartment model was used based on a previous
study of PEG-LD disposition in children (Marina et al, 2002) and
was able to describe total doxorubicin pharmacokinetics in the
current study. However, both the AIC score and the goodness of
fit were inferior to the two-compartment model (data not shown).
Figure 1 depicts a best-fit line for total doxorubicin concentra-
tion–time data in patient #1 (PEG-LD 8mgm
 2) during cycles 1
and 2. Maximum-likelihood analysis was updated and two
iterations were required to achieve stable estimates of the median
parameters. The mean parameters (CV%) observed in the study
include K10¼0.02h
 1 (61%), V¼1.48lm
 2 (29%), K12¼0.21
(140%) h
 1, and K21¼0.64h
 1 (69%). Total doxorubicin pharma-
cokinetic parameters by patient are listed in Table 5. The
interindividual variability in total doxorubicin clearance was
seven-fold (10–73mLhm
 2) in cycle 1 and over 12-fold (3–
37mlh
 1m
 2) in cycle 2. The correlation between dose and total
doxorubicin clearance was weak (Rs¼0.06). The mean (range)
total doxorubicin clearance decreased from 27 (10–73) mlh
 1m
 2
in cycle 1 to 18 (3–37) mlh
 1m
 2 with the addition of valspodar
in cycle 2 (P¼0.009). A three-fold range in V was observed in cycle
1 and there was no significant difference in V between cycles 1 and
2( P¼0.43). The estimated mean (range) terminal elimination
half-life was 89h (40–336h) in cycle 2, much longer than
estimated in cycle 1 (P¼0.001). The AUC was also slightly higher
in cycle 2 (mean 1689mghml
 1, range 492–6257mghml
 1) than
in cycle 1 (mean 1087mghml
 1, range 343–2408mghml
 1;
P¼0.04). In this small set of patients, neither toxicity nor
response was clearly related to total doxorubicin AUC or clearance.
DISCUSSION
Clinical trials in solid tumour malignancies using the P-glyco-
protein modulator, valspodar, combined with single agent etoposide,
doxorubicin, paclitaxel, or vinblastine have required dose reduc-
tions of the antineoplastic agents (Boote et al, 1996; Giaccone et al,
1997; Fracasso et al, 2000; Bates et al, 2001, 2004; Chico et al, 2001;
Minami et al, 2001). These dose reductions are necessary in order
to reduce toxicity due to the decreased clearance and increased
AUC of these agents when given in combination with valspodar. A
theoretical concern has been that these dose reductions may limit
drug exposure to the tumour, thereby decreasing tumour cell kill.
Combining valspodar with PEG-LD may overcome this limitation
as animal studies have revealed no pharmacokinetic interactions
between these drugs (Krishna and Mayer, 1997; Krishna et al, 1999,
2000). In addition, since liposomes reduce the exposure of
entrapped anticancer agent to susceptible tissues while increasing
the drug delivery to tumours, PEG-LD may provide maximal drug
intensity with minimal toxicity (Krishna and Mayer, 1999). In this
study, we demonstrated that valspodar can be given safely with
acceptable toxicity at PEG-LD 25mgm
 2 every 2 weeks. There was
no DLT at this dose level after cycle 2 (PEG-LD and valspodar). No
further dose escalation was attempted as we reasoned that PEG-LD
25mgm
 2 every 2 weeks equaled the cumulative dose of
50mgm
 2 every 4 weeks, the approved dose of PEG-LD used in
the treatment of breast and ovarian carcinoma. More importantly,
most patients required dose reductions due to PPE or neutropenia
after multiple cycles of this combination at this dose level as well as
at lower dose levels. When administered on this schedule, the
pharmacokinetics of total doxorubicin in combination with
valspodar was moderately affected.
The pharmacokinetic data collected in this study suggested that
valspodar does moderately increase plasma levels and decrease the
clearance of total doxorubicin. Nevertheless, this reduced clear-
ance seemed to have little effect on the toxicity profile of PEG-LD
when given at the 25mgm
 2 dose. Large interpatient variability
(seven-fold in cycle 1 and 12-fold in cycle 2) in total doxorubicin
clearance was evident, which was consistent with that found in
other adult studies (4–40 fold) (Gabizon et al, 1991, 1994;
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Figure 1 Plasma doxorubicin concentration vs time plot in patient 1
after receiving intravenous doxorubicin at 20mgm
 2 over 60min in cycle
1. A second intravenous doxorubicin dose at 8mgm
 2 was started 14 days
(336h) after the first dose in combination with valspodar at a dosing rate of
1.42mgkg
 1h
 1 over 2h, followed by 0.42mgkg
 1h
 1 over an additional
70h. Symbols represent measured plasma doxorubicin concentrations, and
the solid line represents the best fit from the maximum likelihood
estimation using ADAPT II software.
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sAmantea et al, 1997). One patient (#6) had a dramatic decrease in
clearance in cycle 2 with resulting high AUC. The patient was on
no other known inhibitors of cytochrome P450 and the mechanism
for this observation is not clear. The long half-life is not surprising
for a pegylated liposomal drug and increased doxorubicin release
was previously demonstrated in preclinical and clinical studies
with this composition (Papahadjopoulos et al, 1991; Gabizon, 1992;
Huang et al, 1994; Amantea et al, 1997). During the second cycle in
which PEG-LD and valspodar are combined, the total doxorubicin
half-life is even longer. This apparent increase in total doxorubicin
half-life during second cycle could be in part an artefact of ‘carry-
over’ from cycle 1 rather than purely a pharmacokinetic
interaction between valspodar and doxorubicin. However, three
patients (Patients #7, 9, and 11) who had no residual plasma
doxorubicin prior to their second cycle, all consistently had 50%
reduction in total doxorubicin clearance in cycle 2 supporting the
conclusion that this finding was not an estimation artefact from
the residual drug. Therefore, the reduction in total doxorubicin
clearance with the addition of valspodar in cycle 2 was likely a
result of a pharmacokinetic interaction, similar to that seen in
other models where the clearance of single agent cytotoxic agents
such as etoposide, doxorubicin, paclitaxel, and vinblastine was
significantly reduced by valspodar administration (Boote et al,
1996; Giaccone et al, 1997; Fracasso et al, 2000; Bates et al, 2001,
2004; Chico et al, 2001; Minami et al, 2001). An influence of
repeated administrations of PEG-LD on this interaction could not
be assessed, as all patients received valspodar in combination with
PEG-LD after cycle 1.
Despite this effect on total doxorubicin clearance, valspodar did
not seem to significantly alter the toxicities of PEG-LD. Patients
Table 5 Patient pharmacokinetic parameters
PEG-LD (mgm
 2)
Cycle 1 Vd (lm
 2) Cycle 1
Clearance
(mlh
 1m
 2)
Cycle 1
Terminal half-life
(h) Cycle 1
AUC 0-N
(lghml
 1) Cycle 1
Patient # Cycle 2 Cycle 2 Cycle 2 Cycle 2 Cycle 2
1 20 1.4 32 44 622
8 2.3 17 101 492
2 20 0.9 12 63 1693
16 0.9 13 88 1301
3 20 1.6 25 44 789
20 1.8 19 65 1041
4 20 1.4 18 55 1115
20 1.6 17 65 1175
5 20 1.2 17 48 1165
20 1.2 19 52 1082
6 20 1.0 26 50 784
22 1.5 3 336 6257
7 22 0.7 38 40 581
22 1.4 20 48 1090
8 22 1.8 38 43 579
22 2.0 32 45 690
9 25 2.0 22 63 1122
25 1.7 12 102 2470
10 25 1.9 29 48 870
25 1.7 20 60 1299
11 25 2.3 73 34 343
25 1.4 37 40 684
12 25 1.1 11 73 2279
25 0.9 11 83 2348
13 25 1.4 29 48 869
25 1.8 27 55 945
14 25 1.1 10 99 2408
25 1.1 10 101 2767
Mean Cycle 1 1.4 27 54 1087
CV% 32 60 31 58
Mean Cycle 2 1.5 18 89 1689
CV% 27 49 84 88
PEG-LD¼pegylated liposomal doxorubicin.
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swith the highest total doxorubicin AUC (42000mghml
 1) after
cycle 2 of therapy had similar toxicities to other patients.
Myelosuppression, an uncommon toxicity with PEG-LD, did not
appear to be exacerbated by valspodar. Only one patient
experienced grade 3 neutropenia and no episodes of neutropenic
fever occurred. As would be expected, dermatologic and gastro-
intestinal events were more commonly observed. PPE occurred
more often in patients receiving greater than three cycles of PEG-
LD and valspodar and often led to dose reductions. As is the case
with single agent studies with PEG-LD, this toxicity is more
common after cumulative doses of PEG-LD. Nausea and vomiting
occurred more frequently in patients after the first cycle when the
combination therapy was administered as opposed to the first
cycle when only PEG-LD was given as a single agent. This is a
known toxicity with valspodar, although it is possible that the
combination exacerbated this toxicity. Nevertheless, the majority
of these events were grade 1–2 and controllable with antiemetic
therapy.
In conclusion, the combination of PEG-LD 25mgm
 2 given with
a 72h infusion of valspodar can be administered every 2 weeks
with acceptable toxicity. The pharmacokinetic interaction is
moderate. Responses were noted in patients with breast and
ovarian carcinoma at this dose of PEG-LD. However, the 72h
infusion makes this an inconvenient regimen. In addition, there
are more potent third-generation, highly specific, P-glycoprotein
modulators in clinical trials. One such trial in Europe, a phase 2
study with docetaxel and the oral agent, zosuquidar, in women
with metastatic breast carcinoma, is ongoing. Should this be a
positive study, additional studies with PEG-LD and this agent
should be considered in the treatment of breast carcinoma.
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